期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

卡培他滨治疗肿瘤引起手足综合征的Meta分析 被引量：2

Capecitabine-Induced Hand Foot Syndrome:A Meta-analysis
下载PDF
导出
摘要 目的对卡培他滨治疗肿瘤引起手足综合征的系统综述,评估卡培他滨引起手足综合征的发生情况。方法根据关键词检索出文献共689篇,纳入21篇文献进行系统评价。结果针对手足综合征,以相对危险度LnRR为效应指标进行系统评价,与对照组相比,不同给药方案的卡培他滨引起手足综合征的风险不同,以RD为分析指标与LnRR得到的结果相同。结论与对照组相比,Meta分析结果显示卡培他滨不同给药方案发生手足综合征的风险不同。 Objective The purpose of the study was to conduct a Meta-analysis to focus on hand-foot syndrome（HFS） for Capecitabine in treatments of cancers.Methods A comprehensive literature search identified 689 articles published from 1995 to 2012 with key words.Total 21 eligible articles entered the meta-analysis.Result The risks of HFS induced by capecitabine in different treatment regimens were different.The result by RD was the＇ same.Among different tumors,median ages and treatment duration,HFS induced by capecitabine was not significantly different.Conclusion Compared with controlled arm,different capecitabine containing regimens had different potential to induce HFS.
作者 蒲绘华 王洪源
机构地区 北京大学公共卫生学院
出处 《中国医药指南》 2013年第5期31-33,共3页 Guide of China Medicine
关键词 卡培他滨或希罗达 手足综合征或掌跖红斑样变手足皮肤反应 Capecitabine OR Xeloda OR Xelodar Hand Foot Syndrome OR Palmar Plantar Erythrodysesthesia Syndrome or Hand Foot Skin Reaction
分类号 R73 [医药卫生—肿瘤]
  • 相关文献

参考文献23

  • 1Chabner BA,Lynch TJ Jr,Longo DJ.HARRISON’S Manual of Oncology[M].The McGraw-Hill Companies,Inc,2008.
  • 2Aru WS.The Use of Capecitabine in Cancer:Management of the Hand Foot Syndrome[J].Acta Med Indones,2005,37(3):174-176.
  • 3Lassere Y,Hoff P.Management of hand-foot syndrome in patients treated with capecitabine(Xeloda)[J].Eur J Oncol Nurs,2004,8(Suppl1):S31-S40.
  • 4Chen S,Feng X,Li Y,et al.Efficacy and safety of XELOX and FOLFOX6adjuvant chemotherapy following radical total gastrectomy[J].Oncol Lett,2012,3(4):781-786.
  • 5Stockler MR,Harvey VJ,Francis PA,et al.Capecitabine versus classical cyclophosphamide,methotrexate,and fluorouracil as first-line chemotherapy for advanced breast cancer[J].J Clin Oncol,2011,29(34):4498-4504.
  • 6Twelves C,Scheithauer W,McKendrick J,et al.Capecitabine versus5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer:final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy[J].Ann Oncol,2012,23(5):1190-1197.
  • 7Hu W,Shi J,Sheng Y,et al.Clinical study of adjuvant capecitabine monotherapy in Chinese elderly patients(aged55-70)with stage IIa breast cancer[J].Onkologie,2010,33(8/9):433-436.
  • 8Stec R,Bod nar L,Szcz ylik C.Feasibilit y and eff icacy of capecitabine and FOLFIRI in patients aged65years and older with advanced colorectal cancer:a retrospective analysis[J].J Cancer Res Clin Oncol,2010,136(2):283-392.
  • 9Rothenberg M L,Cox J V,But ts C,et al.Capecit abine plus oxaliplatin(XELOX)versus5-fluorouracil/folinic acid plus oxaliplatin(FOLFOX-4)as second-line therapy in metastatic colorectal cancer:a randomized phase III noninferiority study[J].Ann Oncol,2008,19(10):1720-1726.
  • 10Díaz-Rubio E,Taber nero J,Gómez-Espa a A,et al.Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion f luorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer:final report of the Spanish Cooperative Group for the Treatment of DigestiveTumors Trial[J].J Clin Oncol,2007,25(27):4224-4230.

二级参考文献32

  • 1缪建华,陈暑波,张迦维,杭猛.草酸铂联合卡培他滨治疗晚期胃癌的近期疗效分析[J].中国癌症杂志,2004,14(5):439-440. 被引量：8
  • 2陈绍俊,黄海欣,李桂生.卡培他滨与氟尿嘧啶/亚叶酸钙联合奥沙利铂治疗晚期胃癌的随机对照临床研究[J].中国癌症杂志,2007,17(6):483-486. 被引量：10
  • 3Louvet C,Andre T,Tigaud JM,et al.Phase II study of oxaliplatin,fluo-rouracil and folinic acid in locally advanced or metastatic gastric cancer patients.J Clin Oncol,2002,20(23):4543-4548.
  • 4Artru P,Andre T,Tigaud JM,et al.Oxaliplatin(OXA),5-Fluo-rouracil,and Folinic acid(FA)in advanced metastatic gastric carcinoma(AMGC)patients:final results of a multicenter phase II study.Pro Am Soc Clin Oncol,2001,20:165.
  • 5Yeon HP,Jae LL,Beak YR,et al.Capecitabin in combination with Oxaliplatin(XELOX)as a first-line therapy for advanced gastric cancer.Cancer Chemother Pharmacol,2008,61:623-629.
  • 6Chao ying Liu,Qing Sun,Xiaosheng Hang,et al.Multicenter phase Ⅱ study of Capecitabin plus Oxaliplatin as a first-line therapy in Chinede patients with advanced gastric cancer.Anti-Cancer Drugs,2008,19:825-831.
  • 7Field K,Michad M,Leong T.Locally advanced and metastatic gastric cancer:current management and new treatment developments[J].Drugs,2008,68(3):299-317.
  • 8Ohtsu A.Chemotherapy for metastatic gastric cancer:past,present,and future[J].J Gastroenterol,2008,43(4):256-264.
  • 9Kim DY,Kim JH,Lee SH,et al.Phase II study of Oxaliplatin,5-fluorouracil and leucovorin in previously platinum-treated patients with advanced gastric cancer[J].Ann Oncol,2003,14:383-387.
  • 10Sumpter K,Harper-Wynne.Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capeci-tabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF[J].Br J Cancer,2005,92(11):1976-1983.

共引文献24

同被引文献13

引证文献2

二级引证文献16

中国医药指南
2013年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部